<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680767</url>
  </required_header>
  <id_info>
    <org_study_id>17784</org_study_id>
    <secondary_id>J2A-MC-GZGF</secondary_id>
    <secondary_id>2020-003160-60</secondary_id>
    <nct_id>NCT04680767</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Healthy Male Participants</brief_title>
  <official_title>Disposition of [¹⁴C]-LY3502970 Following Oral Administration in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure how much of the study drug gets into the&#xD;
      bloodstream and how long it takes the body to eliminate it. This study will involve a single&#xD;
      dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be&#xD;
      incorporated into the study drug. The purposes are to investigate the study drug and its&#xD;
      breakdown products and to find out how much of these pass from blood into urine and feces.&#xD;
      The study will last up to 8 weeks (maximum).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Actual">July 3, 2021</completion_date>
  <primary_completion_date type="Actual">July 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Fecal Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK): Area under the Concentration-Time Curve (AUC) of LY3502970</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Plasma PK: AUC of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK: Maximum Concentration (Cmax) of LY3502970</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Plasma PK: Cmax of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and Whole Blood PK of Radioactivity: AUC</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Plasma and Whole Blood PK of Radioactivity: AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and Whole Blood PK of Radioactivity: Cmax</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Plasma and Whole Blood PK of Radioactivity: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY3502970 and it's Metabolites in Plasma, Feces, and Urine</measure>
    <time_frame>Predose up to Day 17 after administration of study drug</time_frame>
    <description>Relative Abundance of LY3502970 and it's Metabolites in Plasma, Feces, and Urine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[¹⁴C]-LY3502970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of LY3502970 and [¹⁴C]-LY3502970 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>[¹⁴C]-LY3502970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[¹⁴C]-LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>[¹⁴C]-LY3502970</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males&#xD;
&#xD;
          -  Body weight within 50 and 100 kilograms (kg), inclusive, and body mass index within&#xD;
             the range 18.0 and 32.0 kilograms per square meter (kg/m²) (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
          -  Have significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the investigational product (IP); or of interfering&#xD;
             with the interpretation of data&#xD;
&#xD;
          -  Have a history of Gilbert's syndrome or have total bilirubin level (TBL) above upper&#xD;
             limit of normal (ULN) at screening&#xD;
&#xD;
          -  Have evidence of significant active neuropsychiatric disease, as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Have had any exposure to LY3502970 or any other glucagon-like peptide-1 (GLP-1)&#xD;
             analogs, or other related compounds within the prior 3 months, or any history of&#xD;
             allergies to these medications&#xD;
&#xD;
          -  Are currently enrolled in a clinical study involving an investigational product (IP)&#xD;
             or any other type of medical research judged not to be scientifically or medically&#xD;
             compatible with this study&#xD;
&#xD;
          -  Have participated, within the last 3 months, in a clinical study involving an IP. If&#xD;
             the previous IP has a long half-life, 5 half-lives or 3 months (whichever is longer)&#xD;
             should have passed, prior to check-in&#xD;
&#xD;
          -  Have participated in any clinical trial involving a radiolabeled IP within 12 months&#xD;
             prior to check-in&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV&#xD;
             antibodies&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  Have had exposure to significant diagnostic, therapeutic, or employment-related&#xD;
             radiation within 12 months prior to dosing (e.g., serial x-ray or computed tomography&#xD;
             scans, barium meal, current employment in a job requiring radiation exposure&#xD;
             monitoring)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

